Bridge to Life to Present 12 Studies on Liver Transplant Tech at ILTS 2026
Event summary
- Bridge to Life will present 12 studies (5 oral, 7 poster) at ILTS 2026 in Geneva, May 6-9.
- Presentations focus on hypothermic oxygenated perfusion (HOPE) with VitaSmart™ in liver transplants.
- Topics include pediatric patients, partial grafts, and extended-criteria donors.
- One plenary session and one late-breaking poster presentation included.
- Company sponsoring symposium on machine perfusion strategies.
The big picture
Bridge to Life's extensive presentation schedule at ILTS 2026 underscores the growing importance of machine perfusion technology in liver transplantation. The focus on pediatric and extended-criteria donors highlights how these innovations are addressing critical gaps in organ availability. As transplant centers increasingly adopt these technologies, Bridge to Life's market position could strengthen significantly. The company's symposium suggests a strategic effort to shape industry standards and adoption patterns.
What we're watching
- Technology Validation
- Whether the research presentations will demonstrate expanded use cases for HOPE technology in challenging transplant scenarios.
- Market Positioning
- How Bridge to Life leverages this conference to strengthen its leadership in organ preservation solutions.
- Regulatory Pathways
- The pace at which positive clinical data could accelerate regulatory approvals for expanded indications.
Related topics